Christina Papini
YOU?
Author Swipe
View article: Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M<sup>pro</sup>) with Noncovalent Preclinical Candidate, Mpro61
Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M<sup>pro</sup>) with Noncovalent Preclinical Candidate, Mpro61 Open
SARS-CoV-2 Mpro inhibitors, such as nirmatrelvir, have proven efficacy in clinical use. Nirmatrelvir was developed in a target-based approach against wild-type Mpro, with the anticipation that prolonged usage may cause enrichment of drug-r…
View article: Proof-of-concept studies with a computationally designed M<sup>pro</sup>inhibitor as a synergistic combination regimen alternative to Paxlovid
Proof-of-concept studies with a computationally designed M<sup>pro</sup>inhibitor as a synergistic combination regimen alternative to Paxlovid Open
As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not only on preventing spread through vaccination but also on treating infection with direct-acting antivirals (DAA). The approval of Paxlovid, a SARS-Co…
View article: Exploring APOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer
Exploring APOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer Open
APOBEC3 family members are cytidine deaminases catalyzing conversion of cytidine to uracil. Many studies have established a link between APOBEC3 expression and cancer development and progression, especially APOBEC3A (A3A) and APOBEC3B (A3B…